BioWorld

Nov. 3, 2005

Novavax Publicly Raising $18M To Fund Avian Flu Vaccine Work

Capitalizing on its rising stock price driven by avian flu fears, Novavax Inc. is bringing in $18 million through a public offering to support clinical development. (BioWorld Today) Read More

DOR Buying Gastrotech For $39M In Shares, Milestones

Pricing, Data Leaks, Safety: Biotech's Simmering Stew

AVEO Signs To Help Merck Specialize Oncology Drugs

Lorus Cutting Staff, Directing Funds Toward Clinical Work

Other News To Note

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...

Illustration of Alzheimer's disease in the brain

ADPD 2026: Three inflection points to target Alzheimer’s disease

BioWorld Science

A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...